[
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know",
    "summary": "In the most recent trading session, Johnson & Johnson (JNJ) closed at $155.22, indicating a -1.2% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=b7c7459e7488eb085034f9d17d490d4ceff55e080edd6791ad6ad911af7c327a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750110302,
      "headline": "Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know",
      "id": 135314385,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "In the most recent trading session, Johnson & Johnson (JNJ) closed at $155.22, indicating a -1.2% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=b7c7459e7488eb085034f9d17d490d4ceff55e080edd6791ad6ad911af7c327a"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q1 2025 Update",
    "summary": "AQR Capital's Q1'25 portfolio hits $97.07B, with top picks in AAPL, NVDA, & AMZN. Active portfolio adjustments show a quantitative, diversified approach. See more.",
    "url": "https://finnhub.io/api/news?id=51b45bd42e92498ec52abd010edf461044394127b04a8428f9c402a3b43b4ef8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750108183,
      "headline": "Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q1 2025 Update",
      "id": 135312158,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "AQR Capital's Q1'25 portfolio hits $97.07B, with top picks in AAPL, NVDA, & AMZN. Active portfolio adjustments show a quantitative, diversified approach. See more.",
      "url": "https://finnhub.io/api/news?id=51b45bd42e92498ec52abd010edf461044394127b04a8428f9c402a3b43b4ef8"
    }
  },
  {
    "ts": null,
    "headline": "Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?",
    "summary": "JNJ's Innovative Medicines unit shows a growth trend, defying Stelara LOE and the negative impact of the Part D redesign.",
    "url": "https://finnhub.io/api/news?id=5f33d906adc1b592893ec7877c438cb630f84195085347af1aa3d983c53d2697",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750078800,
      "headline": "Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?",
      "id": 135314386,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ's Innovative Medicines unit shows a growth trend, defying Stelara LOE and the negative impact of the Part D redesign.",
      "url": "https://finnhub.io/api/news?id=5f33d906adc1b592893ec7877c438cb630f84195085347af1aa3d983c53d2697"
    }
  },
  {
    "ts": null,
    "headline": "J&J reports results from antibody combo trial for MM patients",
    "summary": "The investigational combo resulted in an ORR of 78.9%, with over half of the subjects achieving a complete response or better.",
    "url": "https://finnhub.io/api/news?id=e857eac44426e3deff3c9c58c92212550c83ed8861c68c5e26ae6e3a8931bf62",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750074181,
      "headline": "J&J reports results from antibody combo trial for MM patients",
      "id": 135300768,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The investigational combo resulted in an ORR of 78.9%, with over half of the subjects achieving a complete response or better.",
      "url": "https://finnhub.io/api/news?id=e857eac44426e3deff3c9c58c92212550c83ed8861c68c5e26ae6e3a8931bf62"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnsons Dual Targeting Car T Cell Therapy Shows Encouraging First Results In Large B Cell Lymphoma",
    "summary": "the most common type of aggressive lymphoma, a blood cancer that originates in the lymphatic system.1,2 These data were presented as an oral presentation at the 2025 European Hematology Association ...",
    "url": "https://finnhub.io/api/news?id=c087a0d712d780b2a880f3b6cd10b6c9ca9fb7e59f68afa1016252b742b658f2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750065449,
      "headline": "Johnson & Johnsons Dual Targeting Car T Cell Therapy Shows Encouraging First Results In Large B Cell Lymphoma",
      "id": 135300797,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "the most common type of aggressive lymphoma, a blood cancer that originates in the lymphatic system.1,2 These data were presented as an oral presentation at the 2025 European Hematology Association ...",
      "url": "https://finnhub.io/api/news?id=c087a0d712d780b2a880f3b6cd10b6c9ca9fb7e59f68afa1016252b742b658f2"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson - Investigational combination of first-in-class bispecifics TALVEY and TECVAYLI shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease",
    "summary": "MILAN - Johnson & Johnson announced new results from the Phase 2 RedirecTT-1 study evaluating the investigational combination of TALVEY , the first U.S. Food and Drug Administration -approved...",
    "url": "https://finnhub.io/api/news?id=a8167ba0bdb020888f21c0c796b80cc601b126d3ce1624bdc7bb2d17da897a58",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750065317,
      "headline": "Johnson & Johnson - Investigational combination of first-in-class bispecifics TALVEY and TECVAYLI shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease",
      "id": 135300717,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "MILAN - Johnson & Johnson announced new results from the Phase 2 RedirecTT-1 study evaluating the investigational combination of TALVEY , the first U.S. Food and Drug Administration -approved...",
      "url": "https://finnhub.io/api/news?id=a8167ba0bdb020888f21c0c796b80cc601b126d3ce1624bdc7bb2d17da897a58"
    }
  }
]